BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win
If infigratinib gains approval, the drug could challenge BioMarin’s predicted blockbuster, Voxzogo, on the achondroplasia market.
13 February 2026
13 February 2026
If infigratinib gains approval, the drug could challenge BioMarin’s predicted blockbuster, Voxzogo, on the achondroplasia market.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.